Stability and safety considerations for biologics in EU MCQs With Answer

Introduction

This quiz set covers stability and safety considerations for biologic medicines within the European regulatory framework, designed for M.Pharm students preparing for Regulatory Aspects of Herbal and Biologicals (MRA202T). The questions focus on key guidelines (ICH, EMA/CHMP), stability testing approaches (real-time, accelerated, photostability), cold chain and distribution requirements, container-closure interactions, potency and purity assays, immunogenicity and aggregation risks, and post-marketing obligations such as pharmacovigilance and batch traceability. Each MCQ reinforces regulatory expectations, critical quality attributes, and practical controls needed to ensure biologic product quality, safety and efficacy through development, release and lifecycle management.

Q1. Which ICH guideline specifically addresses stability testing of biotechnological/biological products?

• ICH Q1A(R2) — Stability Testing of New Drug Substances and Products
• ICH Q5C — Stability of Biotechnological/Biological Products
• ICH Q6A — Specifications: Test Procedures and Acceptance Criteria
• ICH Q3A — Impurities in New Drug Substances

Correct Answer: ICH Q5C — Stability of Biotechnological/Biological Products

Q2. Which EMA/CHMP document provides primary guidance for demonstrating comparability of a biosimilar to a reference biological product?

• EMA Guideline on Quality Risk Management
• EMA Guideline on Similar Biological Medicinal Products (Biosimilars)
• EMA Guideline on Non-Clinical Safety Studies
• EMA Guideline on Paediatric Investigation Plans

Correct Answer: EMA Guideline on Similar Biological Medicinal Products (Biosimilars)

Q3. What stability-related process in biologics most directly increases immunogenicity risk?

• Chemical deamidation of amino acids
• Protein aggregation and formation of particles
• Loss of small-molecule excipients
• Changes in pH within acceptable limits

Correct Answer: Protein aggregation and formation of particles

Q4. Which statement best describes the purpose of real-time stability studies for biologics?

• To rapidly force degradation under extreme conditions to identify degradation products
• To determine shelf-life under the proposed storage conditions over time
• To replace all clinical testing with in vitro assays
• To evaluate container-closure system only

Correct Answer: To determine shelf-life under the proposed storage conditions over time

Q5. What is the commonly recommended storage temperature range for many marketed monoclonal antibody products in the EU?

• Below −20 °C (frozen storage)
• 2 °C to 8 °C (refrigerated)
• 15 °C to 25 °C (room temperature)
• −196 °C (liquid nitrogen)

Correct Answer: 2 °C to 8 °C (refrigerated)

Q6. Which ICH guideline describes photostability testing of new drug substances and products?

• ICH Q3C — Impurities: Residual Solvents
• ICH Q1B — Photostability Testing of New Drug Substances and Products
• ICH Q5E — Comparability of Biotechnological/Biological Products
• ICH Q2(R1) — Validation of Analytical Procedures

Correct Answer: ICH Q1B — Photostability Testing of New Drug Substances and Products

Q7. In the EU, what is the primary responsibility of the Qualified Person (QP) regarding biologic batches?

• To design the clinical trial protocol for the product
• To certify that each released batch complies with marketing authorization and GMP
• To market the product and set the price
• To perform routine stability testing in the commercial lab

Correct Answer: To certify that each released batch complies with marketing authorization and GMP

Q8. Which assay is the regulatory standard for detecting bacterial endotoxin contamination in biologic drug products?

• Plate count method
• Limulus Amebocyte Lysate (LAL) test
• Polymerase chain reaction (PCR) for bacterial DNA
• Chromogenic protein assay

Correct Answer: Limulus Amebocyte Lysate (LAL) test

Q9. What is the main objective of a Risk Management Plan (RMP) for a biological medicine in the EU?

• To provide manufacturing batch records for inspection
• To identify, characterize and minimize safety risks throughout the product lifecycle
• To define commercial launch strategies and pricing
• To replace relabeling requirements during distribution

Correct Answer: To identify, characterize and minimize safety risks throughout the product lifecycle

Q10. According to EU good distribution practice for biologics, what is critical for cold chain maintenance?

• Documenting only the start and end temperatures of shipment
• Maintaining the specified temperature range during storage and transport with monitoring
• Using insulated packaging without temperature monitoring
• Storing all biologics at −80 °C regardless of label

Correct Answer: Maintaining the specified temperature range during storage and transport with monitoring

Q11. How is “shelf-life” defined for a biologic medicinal product?

• The date when marketing authorization expires
• The period during which the product is expected to remain within approved specifications under recommended storage
• The time until the first adverse reaction is reported
• The time allowed between batch manufacture and initial quality control testing

Correct Answer: The period during which the product is expected to remain within approved specifications under recommended storage

Q12. What does a comparability exercise typically demonstrate after a manufacturing process change for a biologic?

• That the product is bioequivalent to an unrelated reference drug
• That the change has no adverse impact on quality, safety or efficacy of the product
• That clinical trials can be waived for the post-change product in all cases
• That only impurity profiles are different but not relevant

Correct Answer: That the change has no adverse impact on quality, safety or efficacy of the product

Q13. Which container-closure interaction is a particular concern for protein biologics stability?

• Protein adsorption to glass or elastomeric surfaces leading to loss of active drug
• Color change of the external carton during shipping
• Evaporation of volatile organic solvents
• Metal corrosion of secondary packaging

Correct Answer: Protein adsorption to glass or elastomeric surfaces leading to loss of active drug

Q14. What characteristic should a stability-indicating assay for a biologic measure?

• Only the total protein concentration regardless of activity
• Biological potency that is sensitive to relevant degradation-induced changes
• The color and odor of the solution
• The viscosity at a single fixed temperature only

Correct Answer: Biological potency that is sensitive to relevant degradation-induced changes

Q15. In accelerated stability testing for biologics, what condition is most commonly used to accelerate degradation?

• Lowering pH to extreme values only
• Elevated temperature to accelerate chemical and physical degradation
• Complete dehydration of the product
• Exposure to ultraviolet radiation only

Correct Answer: Elevated temperature to accelerate chemical and physical degradation

Q16. Which mitigation is recommended to protect biologics from light-induced degradation?

• Light-protective primary or secondary packaging and validated photostability data
• Using transparent containers and labeling “keep in daylight”
• Storing products at −196 °C to avoid light exposure
• Removing all buffers that absorb light

Correct Answer: Light-protective primary or secondary packaging and validated photostability data

Q17. What is a common consequence of repeated freeze–thaw cycles on protein biologics?

• Increased microbial sterility
• Protein aggregation and loss of biological activity
• Permanent reduction of solution pH to neutral
• Improved potency due to concentration effects

Correct Answer: Protein aggregation and loss of biological activity

Q18. Which item is generally NOT required as part of the quality dossier for a novel biologic marketing authorization in the EU?

• Primary amino acid sequence and post-translational modification analysis
• Comprehensive characterization of product-related variants and impurities
• Bioavailability study typical for small-molecule oral drugs
• Stability data under recommended storage conditions

Correct Answer: Bioavailability study typical for small-molecule oral drugs

Q19. Which pharmacovigilance requirement is particularly important for biologics to help identify safety signals?

• Mandatory generic substitution without tracking
• Traceability of product name and batch number in adverse event reports
• Exemption from periodic safety update reports (PSURs)
• Publishing only aggregated sales data annually

Correct Answer: Traceability of product name and batch number in adverse event reports

Q20. Which ICH guideline primarily defines storage conditions and stability testing for the determination of shelf-life of drug products, including biologics?

• ICH Q3B — Impurities: Degradation Products
• ICH Q1A(R2) — Stability Testing: Photostability excluded
• ICH Q1A(R2) — Stability Testing of New Drug Substances and Products
• ICH Q5D — Derivation and Characterisation of Cell Substrates

Correct Answer: ICH Q1A(R2) — Stability Testing of New Drug Substances and Products

Download